Covaxin Vaccine Gains Canadian and U.S. Production Partner

A biopharmaceutical company based in Pennsylvania focused on developing a vaccine to save lives from COVID-19 announced that it had selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for the Covaxin™ vaccine to prepare for potential commercial manufacturing for the US and Canadian markets.

Covaxin is a highly purified and inactivated vaccine developed in collaboration with the Indian Council of Medical Research and Bharat Biotech manufactured using a vero cell manufacturing platform.

Covaxin is currently authorized in thirteen countries.

J.P. Gabriel, Ocugen, Inc.’s Senior Vice President, Manufacturing and Supply Chain, stated in a press release, “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the U.S. FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”

Covaxin clinical studies show potential effectiveness against three key variants of SARS-CoV-2. In addition, these studies suggest that COVAXIN vaccination may be effective against multiple SARS-CoV-2 variants.

Ocugen, Inc. and India-based Bharat Biotech announced on February 2, 2021, a definitive agreement to commercialize Covaxin in the USA, with a later agreement expansion for the Canadian market.